Inoviem Scientific: Advances in Pharmaceutical Development

The Aton Group, listed on Euronext Growth, provides an update on its subsidiary Inoviem Scientific, a pioneer in translational pharmacology. Inoviem is revolutionizing drug development by integrating patients from basic research to clinical trials, thanks to a platform combining biological sampling and artificial intelligence. This personalized approach optimizes the drug lifecycle, ensuring accurate diagnosis and therapeutic guidance.

Currently, Inoviem is conducting two preclinical programs with biopharmaceutical partners, offering rapid analysis of drug candidates on real samples. By reducing research time and costs, it is strengthening its key position in therapeutic development. This addresses a growing demand for models that test the predictability of clinical outcomes.